Hepatitis C
Conditions
Keywords
Hepatitis C, Silymarin, Quality of life
Brief summary
The purpose of this study is to determine the effects of silymarin on outcomes of patients with hepatitis C.
Detailed description
Silymarin has been claimed to have a beneficial effect in various types of liver injury, including alcoholic liver disease, drug and toxin induced hepatotoxicity, and acute and chronic viral hepatitis.
Interventions
DRUGSilymarin
Tab 210 mg, 630 mg, daily, six months.
Sponsors
Isfahan University of Medical Sciences
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
confirmed chronic hepatitis C (HCV Ab (+), HCV RNA (with PCR) (+)) normal or increased liver enzymes (ALT and AST) not using interferon or ribavirin due to patient sensitivity or not consenting.
Exclusion criteria
The pregnant patients patients with side effect which confirmed with rechallenge test
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum aminotransferases (ALT, AST) | at six months after admission | The investigators measured serum amino transferases by commercial AST kit,. ALT kits(Bayer Diagnostics,. Tarrytown, NY, USA) at six months after silymarin admission |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| HCV-RNA | at six months after admission | The investigators measured serum HCV-RNA by Polymerase Chain Reaction (PCR) at six months after silymarin admission |
Countries
Iran
Outcome results
None listed